Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

about

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

Item

http://www.wikidata.org/entity/Q57291693

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 12 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

@en

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

@nl

type

Item

label

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

@en

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

@nl

prefLabel

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

@en

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

@nl

P1476

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease

@en

P2093

Adrian R Parry-Jones

http://www.w3.org/2001/XMLSchema#string

Ana Jovanovic

http://www.w3.org/2001/XMLSchema#string

Craig J Smith

http://www.w3.org/2001/XMLSchema#string

Gillian M Potter

http://www.w3.org/2001/XMLSchema#string

Laura M Parkes

http://www.w3.org/2001/XMLSchema#string

P2860

Enzyme replacement therapy for Anderson-Fabry disease

Age- and sex-specific rates of leukoaraiosis in TIA and stroke patients: population-based study.

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.

Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis.

Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence.

White matter hyperintensity in ischemic stroke patients: it may regress over time

Synovial tissue volume: a treatment target in knee osteoarthritis (OA).

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.

Determinants of white matter hyperintensity burden in patients with Fabry disease.

Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.

P304

e1413-e1422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000006316

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James Stefaniak

Andy Vail

P577

2018-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30209238

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

6177273

http://www.w3.org/2001/XMLSchema#string